SEC Form 4 · accession 0001209191-15-086147

NOVAVAX INC · NVAX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — SVP, Research and Development

Period of report

Dec 16, 2015

Accepted (ET)

Dec 18, 2015 · 5:15 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001000694

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Dec 16, 2015	M	61,886	$1.83	A	61,944	D
Common Stock^F1	Dec 16, 2015	S	61,886	$8.5754	D	58	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to buy)^F2	$1.83	Dec 16, 2015	M	61,886	D	—	Mar 2, 2023	Common Stock	61,886	88,114	D

F1The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.39 to $8.76, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F2Of the 61,886 shares exercised on 12/16/2015 pursuant to this stock option, 37,500 shares vested on 03/02/2014 and 24,386 vested on 03/02/2015. Of the remaining 88,114 shares subject to this stock option, 13,114 vested on 03/02/2015, 37,500 will vest on 03/02/2016, and 37,500 will vest on 03/02/2017.